Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer

por von Plessen, C, Bergman, B, Andresen, O, Bremnes, R M, Sundstrom, S, Gilleryd, M, Stephens, R, Vilsvik, J, Aasebo, U, Sorenson, S
Publicado 2006

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Gro...

por Fløtten, Ø, Grønberg, B H, Bremnes, R, Amundsen, T, Sundstrøm, S, Rolke, H, Hornslien, K, Wentzel-Larsen, T, Aasebø, U, von Plessen, C
Publicado 2012

Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity

por Helbekkmo, N, Sundstrøm, S H, Aasebø, U, Fr Brunsvig, P, von Plessen, C, Hjelde, H H, Garpestad, O K, Bailey, A, Bremnes, R M
Publicado 2007